472 related articles for article (PubMed ID: 11337569)
1. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M
J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569
[TBL] [Abstract][Full Text] [Related]
2. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up.
Wu JQ; Feng HJ; Ouyang W; Sun YG; Chen P; Wang J; Xian JL; Huang LH
Nucl Med Commun; 2015 Aug; 36(8):819-26. PubMed ID: 25932534
[TBL] [Abstract][Full Text] [Related]
3. Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study.
da Fonseca FL; Yamanaka PK; Mazoti L; Arakawa-Sugueno L; Kato JM; Matayoshi S
Head Neck; 2017 Dec; 39(12):2381-2396. PubMed ID: 28945293
[TBL] [Abstract][Full Text] [Related]
4. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
5. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
6. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
[TBL] [Abstract][Full Text] [Related]
7. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study.
Klein Hesselink EN; Brouwers AH; de Jong JR; van der Horst-Schrivers AN; Coppes RP; Lefrandt JD; Jager PL; Vissink A; Links TP
J Nucl Med; 2016 Nov; 57(11):1685-1691. PubMed ID: 27339871
[TBL] [Abstract][Full Text] [Related]
8. [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy].
Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Kalina S; Clausen M; Henze E
Nuklearmedizin; 1997 Apr; 36(3):103-9. PubMed ID: 9162904
[TBL] [Abstract][Full Text] [Related]
9. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin.
Rosario PW; Calsolari MR
Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908
[TBL] [Abstract][Full Text] [Related]
10. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study.
Zettinig G; Hanselmayer G; Fueger BJ; Hofmann A; Pirich C; Nepp J; Dudczak R
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1428-32. PubMed ID: 12397459
[TBL] [Abstract][Full Text] [Related]
11. Sicca complex among Egyptian patients with chronic hepatitis C virus infection.
Nawito Z; Amin A; El-Fadl SA; Abu El Einen K
Clin Rheumatol; 2011 Oct; 30(10):1299-304. PubMed ID: 21487733
[TBL] [Abstract][Full Text] [Related]
12. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment.
Caglar M; Tuncel M; Alpar R
Clin Nucl Med; 2002 Nov; 27(11):767-71. PubMed ID: 12394122
[TBL] [Abstract][Full Text] [Related]
13. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
[TBL] [Abstract][Full Text] [Related]
14. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.
Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Tönshoff G; Sippel C; Wolf H; Clausen M; Henze E
Nucl Med Commun; 1996 Aug; 17(8):681-6. PubMed ID: 8878127
[TBL] [Abstract][Full Text] [Related]
15. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
[TBL] [Abstract][Full Text] [Related]
16. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy.
Raza H; Khan AU; Hameed A; Khan A
Nucl Med Commun; 2006 Jun; 27(6):495-9. PubMed ID: 16710103
[TBL] [Abstract][Full Text] [Related]
17. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139
[TBL] [Abstract][Full Text] [Related]
18. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M
Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
[TBL] [Abstract][Full Text] [Related]
19. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer.
Almeida JP; Sanabria AE; Lima EN; Kowalski LP
Head Neck; 2011 May; 33(5):686-90. PubMed ID: 21484917
[TBL] [Abstract][Full Text] [Related]
20. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up.
Baudin C; Bressand A; Buffet C; Menegaux F; Soret M; Lê AT; Cardon T; Broggio D; Bassinet C; Huet C; Armengol G; Richardson DB; Leenhardt L; Bernier MO; Lussey-Lepoutre C
Thyroid; 2023 Sep; 33(9):1100-1109. PubMed ID: 37300484
[No Abstract] [Full Text] [Related]
[Next] [New Search]